Company news

Syntara Limited news in 2026

Syntara Limited's news releases, calls and decks from 2026, newest first.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Notice of Annual General Meeting/Proxy Form

October 19, 2026

Investor Presentation Canaccord Drug & Device Conference

October 12, 2026

Further significant results from SNT-4728 iRBD Phase 2 trial

October 6, 2026

Notification regarding unquoted securities - SNT

October 4, 2026

Notification regarding unquoted securities - SNT

October 4, 2026

Syntara expands SNT-9465 skin scarring study

September 30, 2026

Syntara receives A$4.7m R&D Tax Incentive

September 20, 2026

Application for quotation of securities - SNT

September 14, 2026

Notification of 2026 AGM Date

September 14, 2026

Appendix 4E and Annual Report

August 27, 2026

Appendix 4G and Corporate Governance Statement

August 27, 2026

Investor Update Webinar Presentation

July 27, 2026

Encouraging SNT-4728 Phase 2 iRBD results

July 5, 2026

Results of Share Purchase Plan

June 10, 2026

Share Purchase Plan Offer Booklet

May 13, 2026

$8m placement and share purchase plan

April 29, 2026

Continuation of trading halt

April 28, 2026

Positive FDA feedback for Amsulostat P2b trial

April 27, 2026

Half Year Report and Appendix 4D

February 25, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 28, 2026

Amsulostat and Garvan in MRFF funded pancreatic trial

January 20, 2026

SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited

January 7, 2026

Decks in 2026